financetom
Business
financetom
/
Business
/
Navigation equipment maker Trimble raises annual forecasts
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Navigation equipment maker Trimble raises annual forecasts
Aug 6, 2025 8:45 AM

Aug 6 (Reuters) - Trimble raised its annual

revenue and profit forecasts on Wednesday, betting on growing

demand for its integrated hardware and software solutions from

industries such as construction, transportation and geospatial.

The navigation equipment maker said bundling its solutions

in prepackaged product suites has helped improve its sales.

Trimble also helps customers by analyzing technical drawings

or blueprints with the help of artificial intelligence tools.

"Looking beyond the next couple of years, we are optimistic

about what an AI forward future will mean to Trimble," said CEO

Rob Painter.

Shares of the company were up about 1% in morning trading.

They have risen about 17% so far this year.

Trimble now expects annual revenue to be between $3.48

billion and $3.56 billion, compared with its prior projection of

$3.37 billion to $3.47 billion.

The company also forecast its annual adjusted profit per

share of $2.90 to $3.06, up from $2.76 to $2.98 previously.

Trimble posted a surprise increase of 1% in second-quarter

revenue to $875.7 million, compared with analysts' average

estimate of $834.3 million, according to data compiled by LSEG.

Its adjusted profit came in at 71 cents per share, above

analysts' average estimate of 63 cents.

(Reporting by Jaspreet Singh in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials
Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials
Dec 3, 2024
07:59 AM EST, 12/03/2024 (MT Newswires) -- Aptose Biosciences ( APTO ) , a precision oncology company, on Tuesday said it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The NCI and Aptose will collaborate on developing Aptose's compound tuspetinib (TUS), an inhibitor of key signaling kinases involved in certain malignancies, in...
Roivant Sciences' Kinevant Says Pulmonary Sarcoidosis Drug Candidate Fails to Meet Goals
Roivant Sciences' Kinevant Says Pulmonary Sarcoidosis Drug Candidate Fails to Meet Goals
Dec 3, 2024
07:59 AM EST, 12/03/2024 (MT Newswires) -- Roivant Sciences ( ROIV ) said Tuesday its Kinevant Sciences unit's phase 2 Resolve-Lung trial for namilumab in chronic active pulmonary sarcoidosis failed to meet its primary and secondary endpoints. Namilumab failed to meet the primary endpoint, showing no treatment benefit over placebo in reducing Rescue Events during the double-blind period. Secondary endpoints,...
Update: AT&T Targets $40 Billion Shareholder Return in 2025 to 2027
Update: AT&T Targets $40 Billion Shareholder Return in 2025 to 2027
Dec 3, 2024
07:56 AM EST, 12/03/2024 (MT Newswires) -- (Updates with additional details from the fifth paragraph.) AT&T ( T ) said Tuesday that it expects more than $50 billion of free cash flow over the next three years and will return at least $40 billion to shareholders through dividends and buybacks. The company said it plans to maintain its current annualized...
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation
Dec 3, 2024
07:55 AM EST, 12/03/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday the US Food and Drug Administration has granted breakthrough therapy designation to sacituzumab tirumotecan, a treatment for certain times of non-small cell lung cancer. The designation is based on data from the phase 2 expansion group of a phase 1/2 study, as well as data from two...
Copyright 2023-2026 - www.financetom.com All Rights Reserved